TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$118 Million


Initial Public Offering

Bookrunner, June 2018

Aptinyx is a clinical-stage biotechnology company developing novel small molecules targeting the N-methyl-D-aspartate receptors, which are vital to normal and effective brain and nervous system functions, for the treatment of CNS disorders.